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A B S T R A C T
We report a patientwith biotinidase deﬁciencywith peculiar ﬁndings on herMRI brain. Subcortical cysts
combined with Dandy Walker cyst on the brain MRI have never been reported.
There are many documented case reports of biotinidase deﬁciency and several of them have included
ﬁndings on neuroimaging. Subcortical cysts have been documented in one patient with biotinidase
deﬁciency previously and on autopsy in one other patient. Video EEG on the same patient showed
evidence of symptomatic generalized epilepsy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Biotinidase (BTD) deﬁciency is an autosomal recessive
genetic disorder where the lack of biotinidase results in a
biochemical inability to free biotin from its protein bound form
and make it available as a cofactor for biotin-dependent
carboxylases. These enzymes are responsible for fatty acid
synthesis, amino acid catabolism, and gluconeogenesis. Biotini-
dase enzyme deﬁciency is caused by a mutation in the BTD gene.
More than 80 mutations have been identiﬁed in the BTD gene at
chromosome locus 3p25 to date. Biotinidase deﬁciency is not
rare with an estimated incidence of almost 1 in 60,000 live births
and can present at any time from 1 week to 10 years of age.
Carrier frequency is about 1:120 in the general population.
Targeted mutation, sequence, deletion/duplication analysis and
simple ﬂurometric enzyme assay can help determine the
diagnosis. Profound (<10% of mean normal serum enzyme
activity) and partial (10–30% of mean normal serum enzyme
activity) deﬁciencies can occur.
Biotinidase deﬁciency, ﬁrst distinguished in the early 1980’s,
has been recognized to cause a wide spectrum of disease.
Neurological manifestations include visual impairment (optic
atrophy, scotomas), sensorineural hearing loss, seizures (myoclon-
ic, partial seizures, tonic–clonic or infantile spasms), ataxia,* Corresponding author at: NYU Langone Medical Center, Department of
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doi:10.1016/j.seizure.2010.10.001neuropathy, and hypotonia. Spinal cord disease is rare but clinical
manifestations with progressive spastic paraparesis and ascending
weakness have been reported. Biotinidase deﬁciency can also lead
to dermatological disease (seborrheic or atopic dermatitis,
alopecia, candidiasis, hair loss, conjunctivitis), immunological
deﬁcits, respiratory impairments (tachypnea, hyperventilation,
apnea, stridor), feeding and gastrointestinal problems (vomiting,
diarrhea), and hepatosplenomegaly. Acute metabolic acidosis may
prove to be lethal, if untreated. Screening has been implemented in
some areas as the signs and symptoms of the disease are
preventable with early treatment. Early initiation of treatment
has been shown to prevent further manifestations of the disease
and many ﬁndings are reversible. The limit of what deﬁcits are
irreversible when treatment is delayed is not well deﬁned. Early
treatment can prevent hearing loss in childrenwith null mutations
in the BTD gene. The pathological correlates for clinical disease and
response to treatment are also not frequently correlated in the
literature. No other phenotypes are believed to be associated with
mutations in the BTD gene.
2. Clinical report
Our patient was a 22 year old womanwhowas the only child of
two healthy non-consanguinous African American parents. She
was born full term after a normal pregnancy with normal
development until 7 months when she had multiple episodes of
respiratory distress, once requiring intubation for apnea. The
patient had visual and auditory decline, developmental regression
and hair loss. She also began having seizures characterized by
rocking movements, loss of consciousness, head/eye turning, andvier Ltd. All rights reserved.
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clonic movements of one or both arms.
The diagnosis of biotinidase deﬁciency was made with genetic
testing that revealed carrier status in both parents. The patient was
subsequently started on biotin supplementation at age 3 with
resolution of alopecia but without improvement of her neurologi-
cal deﬁcits or seizures.
On examination, she was a thin-built womanwhowas alert but
deaf and blind. She was non-verbal but repeatedly made few
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Fig. 1. EEG 1 (a) interictal recording showing multifocal epileptiform discharges. (b)grunting sounds. Her self-stimulatory behavior included head
banging and hand writhing movements. Truncal tone was
decreased. She had increased spasticity in the lower extremities
with sustained ankle clonus bilaterally. The patient was wheel-
chair bound.
Routine and Video EEGmonitoring revealed diffuse generalized
slowing with extremely frequent multifocal (left more than right)
and generalized frontally predominant bursts of spikes and slow
spikes and slow waves (see Fig. 1a); her seizures appeared to havegeneralized ictal onset with slight amplitude asymmetry, left higher than right.
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Fig. 2. (a) MRI brain with FLAIR sequences demonstrating subcortical cysts in the bifrontal areas. (b) T2 weighted image showing thickened calvarium and Dandy Walker
variant.
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with amplitude asymmetry (left more than right; see Fig. 1b). She
remained seizure free on a combination of valproic acid and
levetiracetam. It is interesting that a recent study in rats has shown
that the use of depakote can signiﬁcantly decrease the levels of
serum and liver tissue biotinidase enzyme activity.1 MRI brain (see
Fig. 2a) showed generalized atrophy, Dandy Walker variant (see
Fig. 2b), cystic encephalomalacia in bifrontal and anterior temporal
lobes and periatrial white matter. Cervical spine MRI showed no
spinal cord abnormality.3. Discussion
Various neuroimaging ﬁndings have been reported in patients
with biotinidase deﬁciency such as cerebral atrophy, ventriculo-
megaly, widened extracerebral spaces, subdural effusions, caudate
involvement, basal ganglia calciﬁcations, cortical abnormalities in
the parieto-occipital region and restricted diffusion on DWI.2,3
Spinal cord ﬁndings have included myelopathy.4 and extensive
marked medullary, cervical or thoracic spinal cord demyelination
in three Chinese patients.5
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periventricular white matter and caudothalamic regions. MRI
often demonstrates atrophy with compensatory ventricolomegaly
and may also show edema.6 There have been previous case reports
of diffuse periventricular hypodensities particularly in the frontal
regions on the CT scan of the brain that resolved completely with
treatment.7,8 Cystic degeneration has also been reported.9 Serial
CT-scan and MRI studies of the brain have demonstrated a distinct
pattern of changes from diffuse low attenuation of the white
matter followed by progressive marked cerebral atrophy, which
was reversed following biotin treatment.
Subcortical spongy lesions have been reported on autopsy and
on microscopic examination were characterized by loss of
myelination, sponginess, rarefaction and microcysts with an
increase in vascularity of the lesions.10 Necrotizing lesions similar
to lesions seen in Leigh’s disease or Wernicke’s encephalopathy
have been reported. However, the most affected areas are the
hippocampal and parahippocampal cortex.11 While some MRI and
clinical ﬁndings are reversible, some have not been. Cerebral
atrophy has been reported to be reversible with early biotin
treatment.8,12 In our patient destructive lesions were permanent
despite treatment since age 3. This demonstrates the irreversibility
of brain damage in patients who fail to have biotin supplementa-
tion. The lack of normalization of the MRI correlates clinically as
the patient failed to improve neurologically. 1H-MR spectroscopy
ﬁndings have been reported in a small series of four patients that
include high lactate peak, reversal of the choline/creatinine ratio
and decreased NAA peaks.2 Lactate, pyruvate and 3-hydroxyiso-
valeric are useful biochemical markers that should be measured in
blood, CSF and brain tissue.13
Published data on Long termmonitoring EEG studies in patients
with biotinidase deﬁciency could not be found on our literature
search. Description of clinical events had raised suspicion of partialextratemporal focus/self-stimulatory behavior and either tonic–
clonic seizures or partial seizures with secondary generalization.
Video EEG supported the diagnosis of symptomatic generalized
epilepsy.
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